Prothena Corporation plc (PRTA) Drops 6.51% on February 11

Equities Staff |

Prothena Corporation plc (PRTA) was one of the Russell 2000's biggest losers for Thursday February 11 as the stock slid 6.51% to $29.89, a loss of $-2.08 per share. Starting at an opening price of $31.21 a share, the stock traded between $29.34 and $31.71 over the course of the trading day. Volume was 432,371 shares over 4,990 trades, against an average daily volume of 463,872 shares and a total float of 31.52 million.

The losses send Prothena Corporation plc down to a market cap of $942.21 million. In the last year, Prothena Corporation plc has traded between $76.42 and $21.05, and its 50-day SMA is currently $54.87 and 200-day SMA is $52.86.

Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Prothena Corporation plc is based out of Dublin, and has some 46 employees. Its CEO is Dale Schenk.

For a complete fundamental analysis analysis of Prothena Corporation plc, check out Equities.com’s Stock Valuation Analysis report for PRTA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is engaged in the investment, acquisition and development of synergistic businesses in an effort to increase and sustain growth and value.

Private Markets

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…